Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.
The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.
Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.
Vimian Group AB (publ) (“Vimian”, the “Group” or the “Company”), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, today announces the listing of and commencementRead more
Vimian Group AB (publ), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, announces its intention to carry out a private placement of shares in theRead more
Following a decade of successfully shaping market leaders across the rapidly evolving animal health market, Fidelio Capital AB (Fidelio) today announced the formation of Vimian – a global and diversified group of innovation-driven companies operating in four fast-growing animal healthRead more